12:21 PM
 | 
Apr 11, 2019
 |  BC Extra  |  Clinical News

Gilead’s NASH combo data suggest benefit, safety

Editor's Note: This article was updated on Apr 11, 2019 at 1:17 PM PDT

Phase II combination data presented by Gilead at EASL could begin to lay the groundwork for what MOAs will be essential parts of combinations in non-alcoholic steatohepatitis.

In a Phase II proof-of-concept trial in 20 patients with NASH presented at the European Association for the Study of the Liver meeting in Vienna, Gilead Sciences Inc. (NASDAQ:GILD) reported that 74% treated with cilofexor (GS-9674) plus firsocostat (GS-0976) showed a decline...

Read the full 324 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >